The Society
More than 35,000 clinicians, scientists and allied health professionals from over 160 countries are part of the ERS community
Become an ERS member
The University of Cambridge is a world-leading research and teaching University, frequently ranked among the top 5 in international ratings. The Department of Medicine is one of the largest in the School of Clinical Medicine, and is predominantly located on the Addenbrooke’s Hospital site. The research in the Department is multidisciplinary, linking basic science and clinics, involving scientists throughout Cambridge, the UK and world-wide. Additionally the Department plays a major role in contributing to patient care at both Addenbrooke’s and Papworth hospitals, with two-thirds of Principal Investigators being clinically active.
Pulmonary hypertension
Global fellowships (return phase only)/European fellowships – in line with current status
Being a part of the Department of Medicine, Prof. Morrell’s laboratory has an access to the state of the art core facilities of the University, such as laboratory animal facility with phenotyping units, electron and confocal microscopy, flow-cytometry, proteomics. The broad network of collaborations allows for team members to acquire new skills and techniques even outside the UK. Through the Papworth Hospital and international collaborations the group has an access to Biobanks.
Researchers, working in Prof. Morrell’s group come from different backgrounds and have their special areas of expertise.
The Department of Medicine contains a vibrant Division of Respiratory Medicine (led by Prof Morrell) focussed on the molecular biology of lung disease, including pulmonary hypertension, cystic fibrosis, interstitial lung disease, COPD and asthma, and acute lung injury. The Division is funded by grants from the Wellcome Trust, EU, MRC, BLF and BHF amongst others. Cambridge has been awarded over £60 million pounds to build a new Heart and Lung Research Institute that will open in 2022.
The Division of Respiratory Medicine has strong links with industry, both big Pharma and the local biotechnology cluster in Cambridge. The Division has a strong programme in transitional respiratory medicine in collaboration with GSK and AstraZeneca – Cambridge Biomedical Campus is the site of AstraZeneca’s new R&D hub. Prof Morrell has established a University spin out company to develop new treatments for pulmonary hypertension, as an example of the entrepreneurial spirit in Cambridge.
The University of Cambridge is a diverse international community and welcomes talented students and scientists from around the world. The University is home to hundreds of international societies which promote cultural ties and provide social opportunities. The Department of Medicine holds weekly open seminars covering various research topics, as well as health and safety training courses. The postdoctoral society offers a wide range of career-oriented seminars and workshops. The group of Prof. Morrell has always been international. Currently there are four research associates and three PhD Students coming outside the UK. The group has as well the experience of hosting visiting scientists from various European countries, as well as North America, Canada, and Australia. Prof. Morrell’s team has a solid track record in obtaining individual fellowships, successfully presenting the research at the national (British Thoracic Society) and international congresses and conferences (European Respiratory Society, Keystone, American Thoracic Society etch).
In the process of applying